Cargando…

Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro

Antibodies are commonly used in organ transplant induction therapy and to treat autoimmune disorders. The effects of some biologics on the human immune system remain incompletely characterized and a deeper understanding of their mechanisms of action may provide useful insights for their clinical app...

Descripción completa

Detalles Bibliográficos
Autores principales: Binder, Christian, Sellberg, Felix, Cvetkovski, Filip, Berglund, Erik, Berglund, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686512/
https://www.ncbi.nlm.nih.gov/pubmed/33262770
http://dx.doi.org/10.3389/fimmu.2020.592553
_version_ 1783613343935758336
author Binder, Christian
Sellberg, Felix
Cvetkovski, Filip
Berglund, Erik
Berglund, David
author_facet Binder, Christian
Sellberg, Felix
Cvetkovski, Filip
Berglund, Erik
Berglund, David
author_sort Binder, Christian
collection PubMed
description Antibodies are commonly used in organ transplant induction therapy and to treat autoimmune disorders. The effects of some biologics on the human immune system remain incompletely characterized and a deeper understanding of their mechanisms of action may provide useful insights for their clinical application. The goal of this study was to contrast the mechanistic properties of siplizumab with Alemtuzumab and rabbit Anti-Thymocyte Globulin (rATG). Mechanistic assay systems investigating antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell phagocytosis and complement-dependent cytotoxicity were used to characterize siplizumab. Further, functional effects of siplizumab, Alemtuzumab, and rATG were investigated in allogeneic mixed lymphocyte reaction. Changes in T cell activation, T cell proliferation and frequency of naïve T cells, memory T cells and regulatory T cells induced by siplizumab, Alemtuzumab and rATG in allogeneic mixed lymphocyte reaction were assessed via flow cytometry. Siplizumab depleted T cells, decreased T cell activation, inhibited T cell proliferation and enriched naïve and bona fide regulatory T cells. Neither Alemtuzumab nor rATG induced the same combination of functional effects. The results presented in this study should be used for further in vitro and in vivo investigations that guide the clinical use of immune modulatory biologics.
format Online
Article
Text
id pubmed-7686512
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76865122020-11-30 Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro Binder, Christian Sellberg, Felix Cvetkovski, Filip Berglund, Erik Berglund, David Front Immunol Immunology Antibodies are commonly used in organ transplant induction therapy and to treat autoimmune disorders. The effects of some biologics on the human immune system remain incompletely characterized and a deeper understanding of their mechanisms of action may provide useful insights for their clinical application. The goal of this study was to contrast the mechanistic properties of siplizumab with Alemtuzumab and rabbit Anti-Thymocyte Globulin (rATG). Mechanistic assay systems investigating antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell phagocytosis and complement-dependent cytotoxicity were used to characterize siplizumab. Further, functional effects of siplizumab, Alemtuzumab, and rATG were investigated in allogeneic mixed lymphocyte reaction. Changes in T cell activation, T cell proliferation and frequency of naïve T cells, memory T cells and regulatory T cells induced by siplizumab, Alemtuzumab and rATG in allogeneic mixed lymphocyte reaction were assessed via flow cytometry. Siplizumab depleted T cells, decreased T cell activation, inhibited T cell proliferation and enriched naïve and bona fide regulatory T cells. Neither Alemtuzumab nor rATG induced the same combination of functional effects. The results presented in this study should be used for further in vitro and in vivo investigations that guide the clinical use of immune modulatory biologics. Frontiers Media S.A. 2020-11-11 /pmc/articles/PMC7686512/ /pubmed/33262770 http://dx.doi.org/10.3389/fimmu.2020.592553 Text en Copyright © 2020 Binder, Sellberg, Cvetkovski, Berglund and Berglund http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Binder, Christian
Sellberg, Felix
Cvetkovski, Filip
Berglund, Erik
Berglund, David
Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
title Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
title_full Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
title_fullStr Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
title_full_unstemmed Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
title_short Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
title_sort siplizumab, an anti-cd2 monoclonal antibody, induces a unique set of immune modulatory effects compared to alemtuzumab and rabbit anti-thymocyte globulin in vitro
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686512/
https://www.ncbi.nlm.nih.gov/pubmed/33262770
http://dx.doi.org/10.3389/fimmu.2020.592553
work_keys_str_mv AT binderchristian siplizumabananticd2monoclonalantibodyinducesauniquesetofimmunemodulatoryeffectscomparedtoalemtuzumabandrabbitantithymocyteglobulininvitro
AT sellbergfelix siplizumabananticd2monoclonalantibodyinducesauniquesetofimmunemodulatoryeffectscomparedtoalemtuzumabandrabbitantithymocyteglobulininvitro
AT cvetkovskifilip siplizumabananticd2monoclonalantibodyinducesauniquesetofimmunemodulatoryeffectscomparedtoalemtuzumabandrabbitantithymocyteglobulininvitro
AT berglunderik siplizumabananticd2monoclonalantibodyinducesauniquesetofimmunemodulatoryeffectscomparedtoalemtuzumabandrabbitantithymocyteglobulininvitro
AT berglunddavid siplizumabananticd2monoclonalantibodyinducesauniquesetofimmunemodulatoryeffectscomparedtoalemtuzumabandrabbitantithymocyteglobulininvitro